Overview Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia Status: Completed Trial end date: 2011-07-01 Target enrollment: Participant gender: Summary This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia. Phase: Phase 2 Details Lead Sponsor: AbbVie (prior sponsor, Abbott)